# Amjevita (adalimumab-atto) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/adalimumab-atto

> The FDA approved Amjevita (adalimumab-atto), sponsored by AMGEN INC (AMGN), on September 23, 2016.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Amjevita (adalimumab-atto) |
| Codes |  |
| Sponsor | AMGEN INC (AMGN) https://sec-api.dev/companies/amgn/catalysts |
| Indications |  |
| Modality | biologic |
| FDA designations | none disclosed |

## Timeline

### September 23, 2016: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761024 ORIG-1 (Type 2 New Active Ingredient and Type 4 New Combination): submission_status AP, submission_status_date 20160923, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22

### July 28, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761024 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20220728, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22

### March 22, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761024 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20230322, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22

### August 14, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761024 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20230814, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22

### August 20, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761024 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20240820, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22

### April 7, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761024 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20250407, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22

### May 20, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761024 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20250520, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/adalimumab-atto.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Amjevita (adalimumab-atto) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/adalimumab-atto

```bibtex
@misc{secapidev_pdufa_adalimumab_atto_20261116,
  title        = {Amjevita (adalimumab-atto) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/adalimumab-atto}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_adalimumab_atto_20261116","title":"Amjevita (adalimumab-atto) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/adalimumab-atto","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
